针对不同细胞病理的小分子用于治疗肌缩性侧面硬化症
Mohamed F Elmansy1,2, Cory T Reidl1, Mizzanoor Rahaman1
1Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois, USA.
Medicinal research reviews
|May 27, 2023
概括
由于疾病异质性,肌缩性侧面硬化症 (ALS) 药物发现面临挑战. 本文审查了针对遗传突变和细胞病理的当前策略,并为更有效的治疗提供了建议.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性神经退行性疾病,治疗选择有限.
- 目前FDA批准的药物对患者的益处很小,这凸显了迫切需要新的治疗策略.
- ALS的特征是运动神经元退化,通常与导致蛋白质聚合的遗传突变有关.
研究的目的:
- 审查过去和现在对ALS的药物发现工作.
- 分析针对基因突变 (SOD1,C9orf72,FUS,TDP-43) 和相关细胞病理的方法.
- 为未来的ALS药物发现方向提供建议.
主要方法:
- 关于ALS药物发现的临床前和临床研究的文献综述.
- 针对基因突变,蛋白质聚合,氧化应激,兴奋毒性,线粒体功能障碍和神经炎症的化合物的分析.
- 在ALS研究中使用的各种临床前模型的比较.
主要成果:
- 已经探索了几种治疗策略,包括针对特定的基因突变和一般细胞病理.
- 药物重定向选已经确定了潜在的ALS治疗方法.
- 临床前模型显示预测治疗疗效的可变性.
结论:
- 尽管有许多方法,但有效的ALS治疗仍然难以捉摸.
- 需要一个更加统一和有效的方向来加速从临床前研究转化有前途的化合物到患者.
- 未来的研究应该集中在克服ALS异质性和改善治疗结果的新策略上.
相关概念视频
02:30siRNA - Small Interfering RNAs
16.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.9K
01:15Parkinson's Disease: Overview
614
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
614
01:22Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
01:22Alzheimer's Disease: Treatment
226
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226